Ishiguro, Nobuhisa http://orcid.org/0000-0001-8594-6345
Morioka, Ichiro
Nakano, Takashi
Furukawa, Masashi
Tanaka, Shintaro
Kinoshita, Masahiro
Manabe, Atsushi
Funding for this research was provided by:
Shionogi
Article History
Received: 17 February 2021
Accepted: 29 July 2021
First Online: 9 August 2021
Declarations
:
: The trial protocol for this study was reviewed/approved by the Hokkaido University Certified Review Board (CRB; approval number 020–005, October 2020). Written informed consent will be obtained from a parent/legal guardian for each enrolled subject and every effort will be made to obtain written informed assent from pediatric subjects according to their capabilities.
: Not applicable.
: NI has received speakers’ bureau honoraria from Maruishi Pharmaceutical Co., Ltd., Alfresa Pharma Corporation, MIYARISAN Pharmaceutical Co., Ltd., SRL, Inc., Meiji Seika Pharma Co., Ltd., and Shionogi & Co., Ltd., and study grants from Shionogi & Co., Ltd. IM has received speakers’ bureau honoraria from Shionogi & Co., Ltd., MSD Co., Ltd., and AbbVie LLC, and study grants from Atom Medical Corp. TN has received speakers’ bureau honoraria from Daiichi Sankyo Co., Ltd., Sanofi K.K., and Mitsubishi Tanabe Pharma Corporation. TN has no competing interests with Shionogi & Co., Ltd. except participation of this study as a non-compensated advisor. MF is an employee of Shionogi & Co., Ltd. ST is an employee of Shionogi & Co., Ltd. MK is an employee and minor shareholder of Shionogi & Co., Ltd. AM has no competing interests with Shionogi & Co., Ltd. except participation of this study as a non-compensated advisor.